Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors

[1]  F. Berthold,et al.  Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed , 2016, BMC Cancer.

[2]  D. V. von Schweinitz,et al.  Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy , 2015, PloS one.

[3]  Julie R. Park,et al.  Neuroblastoma: paradigm for precision medicine. , 2015, Pediatric clinics of North America.

[4]  Siming Gao,et al.  Differential diagnosis of CT images in children with neuroblastomas and ganglioneuroblastomas. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[5]  J. Neuhaus,et al.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Berthold,et al.  Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project , 2014, Pediatric blood & cancer.

[7]  Giorgio Reggiardo,et al.  Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma , 2012, OncoTargets and therapy.

[8]  Y. Guan,et al.  CT and MRI findings of thoracic ganglioneuroma. , 2012, The British journal of radiology.

[9]  J. Rozmus,et al.  Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. , 2012, Journal of pediatric hematology/oncology.

[10]  A. Look,et al.  Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG , 2009, Pediatric blood & cancer.

[11]  Giovanni Cecchetto,et al.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Bruzzi,et al.  Retrospective study of childhood ganglioneuroma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Berthold,et al.  Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Ertel,et al.  Ganglioneuroma : primary tumor or maturation of a suspected neuroblastoma? , 2006, European Spine Journal.

[15]  O. Delattre,et al.  High‐dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification , 2004, Cancer.

[16]  D. Stram,et al.  Revision of the International Neuroblastoma Pathology Classification , 2003, Cancer.

[17]  F. Berthold,et al.  Tumour markers are poor predictors for relapse or progression in neuroblastoma. , 2003, European journal of cancer.

[18]  L. Lau.  NEUROBLASTOMA: A Single Institution's Experience with 128 Children and an Evaluation of Clinical and Biological Prognostic Factors , 2002, Pediatric hematology and oncology.

[19]  F. Berthold,et al.  Metabolic activity and clinical features of primary ganglioneuromas , 2001, Cancer.

[20]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[21]  Hiroyuki Shimada,et al.  Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.

[22]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[23]  A. Green,et al.  Clinical manifestations of ganglioneuroma , 1989, Cancer.

[24]  K. Matthay,et al.  Complete pathologic maturation and regression of stage ivs neuroblastoma without treatment , 1988, Cancer.

[25]  H. Cushing,et al.  The Transformation of a Malignant Paravertebral Sympathicoblastoma into a Benign Ganglioneuroma. , 1927, The American journal of pathology.

[26]  S. Eaton,et al.  Morbidity After Ganglioneuroma Excision: Is Surgery Necessary? , 2010, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  R. Arceci.  Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 , 2009 .

[29]  E. Maor,et al.  Ganglioneuroma: an ’incidentaloma' of childhood , 1998, European Radiology.

[30]  K. Lucas,et al.  Catecholamine metabolites in ganglioneuroma. , 1994, Medical and pediatric oncology.